RXB.L Regulatory News (RXB)

Rex Bionics plc

("Rex Bionics" or the "Company")

Grant of options

19th January 2016: Rex Bionics plc (AIM: RXB) "Rex Bionics" or the "Company"), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, announces that on 18 January 2016 the Board of Rex Bionics granted options ("Options") over 22,988 ordinary shares of 10 pence each in the Company ("Ordinary Shares") to Joseph Cucolo, who as announced on 11 January 2016 has joined the Board as a non-executive Director. The Options represent in aggregate 0.13% of the existing issued share capital.

The Options are being issued under the Company's Share Option Plan, which was established by the Board at Admission. They are exercisable at an exercise price of 43.5 pence per Ordinary Share at any time up to the tenth anniversary of the date of grant, and one third of the options vest at the end of each of the first three anniversaries of the grant.

Joe Cucolo currently holds no Ordinary Shares in the Company

ENDS

For further information please contact:

Rex Bionics Plc

Crispin Simon, Chief Executive

+44 (0) 7 483 167851

Peter Worrall, Chief Financial Officer

+44 (0) 142 864 5416

Stifel Securities Limited (NOMAD and Broker)

Jonathan Senior

+44 (0) 20 7710 7600

Consilium Strategic Communications

Jessica Hodgson / Chris Welsh / Lindsey Neville

rexbionics@consilium-comms.com

+44 (0) 203 709 5700

About Rex Bionics plc

Rex Bionics (AIM: RXB) is the pioneer of the REX Robot that enhances the mobility of wheelchair users and was founded in Auckland, New Zealand by two robotics engineers with first-hand experience of wheelchair users and their needs.

Rex Bionics is working with physiotherapists to develop the concept and practice of Robot-Assisted Physiotherapy (RAP). In a session of RAP, REX lifts patients from a sitting position into a robot-supported standing position, allowing them to take part in a set of supported walking and stretching exercises, designed by specialist physiotherapists.

In addition, REX P, for use in the home, enables users to walk and stand with their hands free - providing more work and recreation options. Our vision is to commercialise an all-day use REX P for a target market segment of wheel chair users with a spinal cord injury, who number around 500,000 people in the US and EU alone.

Wheelchair users are at risk of developing numerous medical complications from extended periods of sitting. By enabling them to spend more time standing, walking and exercising, REX may offer significant health benefits, including improved sleep and maintenance of joint range, and a reduction in spasm, pain, common abdominal problems and prescription drug use.

A programme of "RAPPER" clinical trials is now under way to evaluate these potential benefits and a positive interim analysis of the RAPPER II data was presented on 27th November 2015. Recruitment for RAPPER II remains open and clinics and individuals can send enquiries to rex@physiofunction.co.uk.

Until now, REX has most commonly been used by wheelchair users with a spinal cord injury, but has also been used by people who have suffered a stroke or other traumatic brain injury; and wheelchair users with multiple sclerosis, muscular dystrophy and cerebral palsy.

Rex Bionics has three Strategic Objectives - to establish Robot-Assisted Physiotherapy as a Gold Standard of Care for Spinal Cord Injury, Stroke and other neurological conditions; to establish REX as the market-leading robotic mobility aid; and by effective execution of our plans, to deliver significant value growth to shareholders.

Rex Bionics works with distribution partners in the US (customerservice@enableme.com), China (MAAB, alex-lou@maab-group.com), Hong Kong and Taiwan (Deltason, tommychan@deltason.com), Denmark and Belgium; and in other countries we support customers directly (debra.leeves@rexbionics.com).

Rex Bionics was admitted to trading on the London Stock Exchange's AIM in 2014. REX is not registered for At-Home use in the United States of America.